Pathophysiology of cardiopulmonary bypass: Current strategies for the prevention and treatment of anemia, coagulopathy, and organ dysfunction

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 18, Issue 2, 2014, Pages 161-176

  Esper, Stephen A ^a   Subramaniam, Kathirvel ^a   Tanaka, Kenichi A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

anemia; bivalirudin; cardiopulmonary bypass; coagulopathy; heparin; hyperglycemia; inflammation; neurological complications; renal dysfunction; reperfusion injury

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; ARGATROBAN; CLOPIDOGREL; DABIGATRAN; EPTIFIBATIDE; HEPARIN; HIRULOG; PRASUGREL; RIVAROXABAN; THROMBIN INHIBITOR; TICAGRELOR; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANEMIA; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CORONARY ARTERY BYPASS GRAFT; ERYTHROCYTE TRANSFUSION; EXTRACORPOREAL CIRCULATION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEMODILUTION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFLAMMATION; INTRAOPERATIVE PERIOD; ISCHEMIA; KIDNEY DYSFUNCTION; METABOLIC DISORDER; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; BLOOD COAGULATION DISORDERS; COGNITION DISORDERS; HEART SURGERY;

ANEMIA; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; COGNITION DISORDERS; HEMODILUTION; HUMANS; INFLAMMATION; MULTIPLE ORGAN FAILURE; PLATELET AGGREGATION INHIBITORS;

EID: 84901807528     PISSN: 10892532     EISSN: 19405596     Source Type: Journal    
DOI: 10.1177/1089253214532375     Document Type: Review

References (154)

1. Cohn LH. Fifty years of open-heart surgery. Circulation. 2003 ; 107: 2168-2170
2. Kirklin JW, Dushane JW, Patrick RT, et al. Intracardiac surgery with the aid of a mechanical pump-oxygenator system (gibbon type): report of eight cases. Proc Mayo Clinic. 1955 ; 30: 201-206
3. Warden HE, De Wall RA, Varco RL. Use of the right auricle as a pump for the pulmonary circuit. Surg Forum. 1955 ; 5: 16-22
4. Toomasian JM, Lawson S, Harris WE ECMO: Extracorporeal Cardiopulmonary Support. Annich GM Lynch WR MacLaren G WIlson JM Bartlett RH, ed. Ann Arbor, MI: Extracorporeal Support Organization ; 2012: 107-132.
5. Hessell EA, Hill AG Cardiopulmonary Bypass Principles and Practice. Gravlee GP Davis RF Kurusz M Utley JR, ed. Philadelphia, PA: Lippincott Williams & Wilkins ; 2000: 69-97.
6. Cook DJ, Oliver WC, Orszulak TA, Daly RC, Bryce RD. Cardiopulmonary bypass temperature, hematocrit, and cerebral oxygen delivery in humans. Ann Thorac Surg. 1995 ; 60: 1671-1677
7. Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A. Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: should current practice be changed?. J Thorac Cardiovasc Surg. 2003 ; 125: 1438-1450
8. Karkouti K, Beattie WS, Wijeysundera DN, et al. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg. 2005 ; 129: 391-400
9. Karkouti K, Djaiani G, Borger MA, et al. Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery. Ann Thorac Surg. 2005 ; 80: 1381-1387
10. Brauer SD, Applegate RL, Jameson JJ, et al. Association of plasma dilution with cardiopulmonary bypass-associated bleeding and morbidity. J Cardiothorac Vasc Anesth. 2013 ; 27: 845-852
11. Mathew JP, Mackensen GB, Phillips-Bute B, et al. Effects of extreme hemodilution during cardiac surgery on cognitive function in the elderly. Anesthesiology. 2007 ; 107: 577-584
12. Ranucci M, Conti D, Castelvecchio S, et al. Hematocrit on cardiopulmonary bypass and outcome after coronary surgery in nontransfused patients. Ann Thorac Surg. 2010 ; 89: 11-17
13. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion. 2002 ; 42: 812-818
14. Walpoth BH, Eggensperger N, Hauser SP, et al. Effects of unprocessed and processed cardiopulmonary bypass blood retransfused into patients after cardiac surgery. Int J Artif Organs. 1999 ; 22: 210-216
15. Kincaid EH, Jones TJ, Stump DA, et al. Processing scavenged blood with a cell saver reduces cerebral lipid microembolization. Ann Thorac Surg. 2000 ; 70: 1296-1300
16. Jewell AE, Akowuah EF, Suvarna SK, Braidley P, Hopkinson D, Cooper G. A prospective randomised comparison of cardiotomy suction and cell saver for recycling shed blood during cardiac surgery. Eur J Cardiothorac Surg. 2003 ; 23: 633-636
17. Carrier M, Denault A, Lavoie J, Perrault LP. Randomized controlled trial of pericardial blood processing with a cell-saving device on neurologic markers in elderly patients undergoing coronary artery bypass graft surgery. Ann Thorac Surg. 2006 ; 82: 51-55
18. Burman JF, Westlake AS, Davidson SJ, et al. Study of five cell salvage machines in coronary artery surgery. Transfus Med. 2002 ; 12: 173-179
19. Djaiani G, Fedorko L, Borger MA, et al. Continuous-flow cell saver reduces cognitive decline in elderly patients after coronary bypass surgery. Circulation. 2007 ; 116: 1888-1895
20. Sniecinski RM, Chen EP, Tanaka KA. Reduced levels of fibrin (antithrombin I) and antithrombin III underlie coagulopathy following complex cardiac surgery. Blood Coagul Fibrinolysis. 2008 ; 19: 178-179
21. Vretzakis G, Kleitsaki A, Stamoulis K, et al. The impact of fluid restriction policy in reducing the use of red blood cells in cardiac surgery. Acta Anaesthesiol Belg. 2009 ; 60: 221-228
22. Sakwa MP, Emery RW, Shannon FL, et al. Coronary artery bypass grafting with a minimized cardiopulmonary bypass circuit: a prospective, randomized trial. J Thorac Cardiovasc Surg. 2009 ; 137: 481-485
23. Koster A, Huebler M, Boettcher W, Redlin M, Berger F, Hetzer R. A new miniaturized cardiopulmonary bypass system reduces transfusion requirements during neonatal cardiac surgery: initial experience in 13 consecutive patients. J Thorac Cardiovasc Surg. 2009 ; 137: 1565-1568
24. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990 ; 86: 385-391
25. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 1993 ; 91: 1877-1883
26. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980 ; 56: 824-834
27. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation. 2004 ; 110: e454 - e458
28. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003 ; 76: 2121-2131
29. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001 ; 344: 1286-1292
30. Olinger GN, Hussey CV, Olive JA, Malik MI. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardiovasc Surg. 1984 ; 87: 673-677
31. Selleng S, Lubenow N, Wollert HG, Mullejans B, Greinacher A. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg. 2001 ; 71: 1041-1042
32. Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth. 2000 ; 14: 243-248
33. Apostolidou I, Sweeney MF, Missov E, Joyce LD, John R, Prielipp RC. Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2008 ; 106: 404-408
34. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood. 2004 ; 104: 3072-3077
35. Doepker B, Mount KL, Ryder LJ, Gerlach AT, Murphy CV, Philips GS. Bleeding risk factors associated with argatroban therapy in the critically ill. J Thromb Thrombolysis. 2012 ; 34: 491-498
36. Koster A, Chew D, Grundel M, et al. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg. 2003 ; 96: 1316-1319
37. Koster A, Spiess B, Jurmann M, et al. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial. Anesth Analg. 2006 ; 103: 540-544
38. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006 ; 131: 533-539
39. Merry AF, Raudkivi PJ, Middleton NG, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg. 2004 ; 77: 925-931
40. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008 ; 28: 380-386
41. Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013 ; 128: 1234-1243
42. Tanaka KA, Bolliger D. On the reversal of new oral anti-coagulants: can we simply extrapolate data from the animal models to humans?. Br J Anaesth. 2013 ; 110: 329-332
43. Koster A, Buz S, Krabatsch T, et al. Effect of modified ultrafiltration on bivalirudin elimination and postoperative blood loss after on-pump coronary artery bypass grafting: assessment of different filtration strategies. J Cardiac Surg. 2008 ; 23: 655-658
44. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012 ; 119: 2172-2174
45. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 ; 103: 1116-1127
46. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012 ; 119: 3016-3023
47. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology. 2013 ; 118: 1466-1474
48. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. 2013 ; 41: e42 - e46
49. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 ; 127: 529-555
50. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 ; 141: e326S - e350S
51. Guidelines on myocardial revascularization. Eur Heart J. 2010 ; 31: 2501-2555
52. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 ; 124: 2610-2642
53. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007 ; 153: 66.e9 - e16
54. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010 ; 50: 126-142
55. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi ; 2013 :
56. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009 ; 30: 916-922
57. Kim IS, Choi BR, Jeong YH, Kwak CH, Kim S. The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost. 2009 ; 7: 897-899
58. Pickard AS, Becker RC, Schumock GT, Frye CB. Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. Pharmacotherapy. 2008 ; 28: 376-392
59. Benzon HT, McCarthy RJ, Benzon HA, et al. Determination of residual antiplatelet activity of clopidogrel before neuraxial injections. Br J Anaesth. 2011 ; 107: 966-971
60. Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv. 2012 ; 5: 261-269
61. Goodnough LT, Smith PK, Levy JH, et al. Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. J Thorac Cardiovasc Surg. 2013 ; 145: 1077-1082.e4
62. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 ; 361: 1045-1057
63. Savonitto S, D'Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of "bridging" antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010 ; 104: 285-291
64. Korte W, Cattaneo M, Chassot PG, et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost. 2011 ; 105: 743-749
65. Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery. Heart Lung Circ. 2010 ; 19: 2-10
66. Vickers S, Theoharides AD, Arison B, et al. In vitro and in vivo studies on the metabolism of tirofiban. Drug Metab Dispos. 1999 ; 27: 1360-1366
67. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012 ; 307: 265-274
68. Pruller F, Drexler C, Archan S, Macher S, Raggam RB, Mahla E. Low platelet reactivity is recovered by transfusion of stored platelets: a healthy volunteer in vivo study. J Thromb Haemost. 2011 ; 9: 1670-1673
69. Hansson E, Shams H, Astrom-Olsson K, et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth. 2014 ; 112: 570-575
70. Vilahur G, Choi BG, Zafar MU, et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost. 2007 ; 5: 82-90
71. Zafar MU, Santos-Gallego C, Vorchheimer DA, et al. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. J Thromb Haemost. 2013 ; 11: 100-106
72. Tanaka K, Morimoto T, Yada I, Kusagawa M, Deguchi K. Physiologic role of enhanced fibrinolytic activity during cardiopulmonary bypass in open heart surgery. ASAIO Trans. 1987 ; 33: 505-509
73. Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?. J Cardiovasc Pharmacol. 1996 ; 27: S50 - S57
74. Bokesch PM, Szabo G, Wojdyga R, et al. A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). J Thorac Cardiovasc Surg. 2012 ; 143: 1022-1029
75. Davidson SJ, Burman JF, Rutherford LC, Keogh BF, Yacoub MH. High molecular weight kininogen deficiency: a patient who underwent cardiac surgery. Thromb Haemost. 2001 ; 85: 195-197
76. Journois D, Mauriat P, Pouard P, Marchot P, Amiral J, Safran D. Assessment of coagulation factor activation during cardiopulmonary bypass with a new monoclonal antibody. J Cardiothorac Vasc Anesth. 1994 ; 8: 157-161
77. Kang HM, Kalnoski MH, Frederick M, Chandler WL. The kinetics of plasmin inhibition by aprotinin in vivo. Thromb Res. 2005 ; 115: 327-340
78. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2. Thromb Haemost. 1993 ; 70: 253-258
79. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth. 2009 ; 102: 793-799
80. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA. Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. Br J Anaesth. 2010 ; 104: 318-325
81. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts: blood transfusion. N Engl J Med. 1999 ; 340: 438-447
82. Hung M, Besser M, Sharples LD, Nair SK, Klein AA. The prevalence and association with transfusion, intensive care unit stay and mortality of pre-operative anaemia in a cohort of cardiac surgery patients. Anaesthesia. 2011 ; 66: 812-818
83. van Straten AH, Hamad MA, van Zundert AJ, Martens EJ, Schonberger JP, de Wolf AM. Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting: a comparison with the matched general population. Circulation. 2009 ; 120: 118-125
84. Kulier A, Levin J, Moser R, et al. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation. 2007 ; 116: 471-479
85. Fang WC, Helm RE, Krieger KH, et al. Impact of minimum hematocrit during cardiopulmonary bypass on mortality in patients undergoing coronary artery surgery. Circulation. 1997 ; 96: II-194 - II-199
86. DeFoe GR, Ross CS, Olmstead EM, et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 2001 ; 71: 769-776
87. Loor G, Li L, Sabik JF, Rajeswaran J, Blackstone EH, Koch CG. Nadir hematocrit during cardiopulmonary bypass: end-organ dysfunction and mortality. J Thorac Cardiovasc Surg. 2012 ; 144: 654-662.e4
88. Surgenor SD, DeFoe GR, Fillinger MP, et al. Intraoperative red blood cell transfusion during coronary artery bypass graft surgery increases the risk of postoperative low-output heart failure. Circulation. 2006 ; 114: I43 - I48
89. Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002 ; 74: 1180-1186
90. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006 ; 34: 1608-1616
91. Koch CG, Li L, Duncan AI, et al. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg. 2006 ; 81: 1650-1657
92. Kuduvalli M, Oo AY, Newall N, et al. Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. Eur J Cardiothoracic Surg. 2005 ; 27: 592-598
93. van Straten AH, Bekker MW, Soliman Hamad MA, et al. Transfusion of red blood cells: the impact on short-term and long-term survival after coronary artery bypass grafting, a ten-year follow-up. Interact Cardiovasc Thorac Surg. 2010 ; 10: 37-42
94. Hajjar LA, Vincent JL, Galas FR, et al. Transfusion Requirements After Cardiac Surgery: the TRACS randomized controlled trial. JAMA. 2010 ; 304: 1559-1567
95. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008 ; 358: 1229-1239
96. Kor DJ, Van Buskirk CM, Gajic O. Red blood cell storage lesion. Bosn J Basic Med Sci. 2009 ; 9: 21-27
97. Steiner ME, Assmann SF, Levy JH, et al. Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7). Transfus Apher Sci. 2010 ; 43: 107-116
98. Kuntschen FR, Galletti PM, Hahn C. Glucose-insulin interactions during cardiopulmonary bypass: hypothermia versus normothermia. J Thorac Cardiovasc Surg. 1986 ; 91: 451-459
99. Nagaoka H, Innami R, Watanabe M, Satoh M, Murayama F, Funakoshi N. Preservation of pancreatic beta cell function with pulsatile cardiopulmonary bypass. Ann Thorac Surg. 1989 ; 48: 798-802
100. Minami K, Korner MM, Vyska K, Kleesiek K, Knobl H, Korfer R. Effects of pulsatile perfusion on plasma catecholamine levels and hemodynamics during and after cardiac operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990 ; 99: 82-91
101. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 ; 345: 1359-1367
102. Doenst T, Wijeysundera D, Karkouti K, et al. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2005 ; 130: 1144
103. Ouattara A, Lecomte P, Le Manach Y, et al. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology. 2005 ; 103: 687-694
104. Gandhi GY, Nuttall GA, Abel MD, et al. Intraoperative hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clin Proc. 2005 ; 80: 862-866
105. Gandhi GY, Nuttall GA, Abel MD, et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med. 2007 ; 146: 233-243
106. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009 ; 15: 353-369
107. Hirai S. Systemic inflammatory response syndrome after cardiac surgery under cardiopulmonary bypass. Ann Thorac Cardiovasc Surg. 2003 ; 9: 365-370
108. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003 ; 75: S715 - S720
109. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med. 1981 ; 304: 497-503
110. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993 ; 55: 552-559
111. Wei M, Kuukasjarvi P, Laurikka J, et al. Cytokine responses in low-risk coronary artery bypass surgery. Int J Angiol. 2001 ; 10: 27-30
112. Picone AL, Lutz CJ, Finck C, et al. Multiple sequential insults cause post-pump syndrome. Ann Thorac Surg. 1999 ; 67: 978-985
113. Prondzinsky R, Knupfer A, Loppnow H, et al. Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 ; 129: 760-766
114. Smith PK, Shernan SK, Chen JC, et al. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg. 2011 ; 142: 89-98
115. Hall R. Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. J Cardiothorac Vasc Anesth. 2013 ; 27: 983-1033
116. Landis RC, Arrowsmith JE, Baker RA, et al. Consensus statement: defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surg Forum. 2008 ; 11: E316 - E322
117. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov. 2003 ; 2: 391-405
118. Dieleman JM, Nierich AP, Rosseel PM, et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA. 2012 ; 308: 1761-1767
119. Stahl GL, Shernan SK, Smith PK, Levy JH. Complement activation and cardiac surgery: a novel target for improving outcomes. Anesth Analg. 2012 ; 115: 759-771
120. Mathew JP, Shernan SK, White WD, et al. Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke. 2004 ; 35: 2335-2339
121. Shernan SK, Fitch JC, Nussmeier NA, et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2004 ; 77: 942-949
122. Chan WW, Wong GT, Irwin MG. Perioperative statin therapy. Expert Opin Pharmacother. 2013 ; 14: 831-842
123. Frank A, Bonney M, Bonney S, Weitzel L, Koeppen M, Eckle T. Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin Cardiothorac Vasc Anesth. 2012 ; 16: 123-132
124. Mentzer RM. Myocardial protection in heart surgery. J Cardiovasc Pharmacol Ther. 2011 ; 16: 290-297
125. Yaliniz H, Tokcan A, Zeren H, et al. Effects on reperfusion injury of adding diltiazem to tepid blood cardioplegia. Heart Surg Forum. 2004 ; 7: E434 - E439
126. Chen RH. The scientific basis for hypocalcemic cardioplegia and reperfusion in cardiac surgery. Ann Thorac Surg. 1996 ; 62: 910-914
127. Julia PL, Buckberg GD, Acar C, Partington MT, Sherman MP. Studies of controlled reperfusion after ischemia. XXI. Reperfusate composition: superiority of blood cardioplegia over crystalloid cardioplegia in limiting reperfusion damage - importance of endogenous oxygen free radical scavengers in red blood cells. J Thorac Cardiovasc Surg. 1991 ; 101: 303-313
128. Lellouche F, Dionne S, Simard S, Bussieres J, Dagenais F. High tidal volumes in mechanically ventilated patients increase organ dysfunction after cardiac surgery. Anesthesiology. 2012 ; 116: 1072-1082
129. Tutun U, Parlar AI, Altinay L, et al. Does on-pump normothermic beating-heart valve surgery with low tidal volume ventilation protect the lungs?. Heart Surg Forum. 2011 ; 14: E297 - E301
130. Zupancich E, Paparella D, Turani F, et al. Mechanical ventilation affects inflammatory mediators in patients undergoing cardiopulmonary bypass for cardiac surgery: a randomized clinical trial. J Thorac Cardiovasc Surg. 2005 ; 130: 378-383
131. Sundar S, Novack V, Jervis K, et al. Influence of low tidal volume ventilation on time to extubation in cardiac surgical patients. Anesthesiology. 2011 ; 114: 1102-1110
132. Ouattara A, Sarrabay P. Ann Fra Anesth Reanim. 2012 ; 31: S2 - S4
133. Koch C, Li L, Figueroa P, Mihaljevic T, Svensson L, Blackstone EH. Transfusion and pulmonary morbidity after cardiac surgery. Ann Thorac Surg. 2009 ; 88: 1410-1418
134. Rabiner CJ, Willner AE, Fishman J. Psychiatric complications following coronary bypass surgery. J Nerv Ment Dis. 1975 ; 160: 342-348
135. Stump DA, Rogers AT, Hammon JW, Newman SP. Cerebral emboli and cognitive outcome after cardiac surgery. J Cardiothorac Vasc Anesth. 1996 ; 10: 113-118
136. Young GB, Bolton CF, Archibald YM, Austin TW, Wells GA. The electroencephalogram in sepsis-associated encephalopathy. J Clin Neurophysiol. 1992 ; 9: 145-152
137. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999 ; 34: 1262-1347
138. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001 ; 344: 395-402
139. Patel RL, Turtle MR, Chambers DJ, James DN, Newman S, Venn GE. Alpha-stat acid-base regulation during cardiopulmonary bypass improves neuropsychologic outcome in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1996 ; 111: 1267-1279
140. Grigore AM, Murray CF, Ramakrishna H, Djaiani G. A core review of temperature regimens and neuroprotection during cardiopulmonary bypass: does rewarming rate matter?. Anesth Analg. 2009 ; 109: 1741-1751
141. Joshi B, Brady K, Lee J, et al. Impaired autoregulation of cerebral blood flow during rewarming from hypothermic cardiopulmonary bypass and its potential association with stroke. Anesth Analg. 2010 ; 110: 321-328
142. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med. 1998 ; 128: 194-203
143. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006 ; 1: 19-32
144. Stafford-Smith M, Patel UD, Phillips-Bute BG, Shaw AD, Swaminathan M. Acute kidney injury and chronic kidney disease after cardiac surgery. Adv Chronic Kidney Dis. 2008 ; 15: 257-277
145. Blauth CI. Macroemboli and microemboli during cardiopulmonary bypass. Ann Thorac Surg. 1995 ; 59: 1300-1303
146. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg. 1997 ; 85: 766-782
147. Wright G. Haemolysis during cardiopulmonary bypass: update. Perfusion. 2001 ; 16: 345-351
148. Wenstone R, Campbell JM, Booker PD, McKay R. Renal function after cardiopulmonary bypass in children: comparison of dopamine with dobutamine. Br J Anaesth. 1991 ; 67: 591-594
149. Carcoana OV, Mathew JP, Davis E, et al. Mannitol and dopamine in patients undergoing cardiopulmonary bypass: a randomized clinical trial. Anesth Analg. 2003 ; 97: 1222-1229
150. Bove T, Landoni G, Calabro MG, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation. 2005 ; 111: 3230-3235
151. Mentzer RM, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:The NAPA Trial. J Am Coll Cardiol. 2007 ; 49: 716-726
152. Presta P, Onorati F, Fuiano L, et al. Can pulsatile cardiopulmonary bypass prevent perioperative renal dysfunction during myocardial revascularization in elderly patients?. Nephron Clin Pract. 2009 ; 111: c229 - c235
153. Schwann NM, Horrow JC, Strong MD, Chamchad D, Guerraty A, Wechsler AS. Does off-pump coronary artery bypass reduce the incidence of clinically evident renal dysfunction after multivessel myocardial revascularization?. Anesth Analg. 2004 ; 99: 959-964
154. Asimakopoulos G, Karagounis AP, Valencia O, et al. Renal function after cardiac surgery off- versus on-pump coronary artery bypass: analysis using the Cockroft-Gault formula for estimating creatinine clearance. Ann Thorac Surg. 2005 ; 79: 2024-2031